glp 1 receptor agonists effects on cardiovascular risk reduction Frontiers Glucagon-like peptide 1(GLP-1) receptor agonists
Description
BMC Geriatr
The searches were conducted in adherence to the PRISMA-S guidelines, and were restricted to human studies conducted in August 2024, without any language and date restrictions, unless specified
Significantly, it has been demonstrated that GLP-1 analogues can suppress NF-B, which is a major activator of IL-6 expression [121]
Clinical evidence shows significant improvements in Type 2 diabetes, sleep apnea, and heart health, along with renewed energy, mobility, and emotional balanceproving that surgery changes how the body functions, not just how it looks
GLP-1s arent safe for everyone
